News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
800,857 Results
Type
Article (60159)
Company Profile (712)
Press Release (739969)
Multimedia
Podcasts (167)
Webinars (26)
Section
Business (218007)
Career Advice (2843)
Deals (37714)
Drug Delivery (164)
Drug Development (87331)
Employer Resources (189)
FDA (18109)
Job Trends (16146)
News (372529)
Policy (37304)
Tag
2027 BioCapital Elite (1)
2027 BioMidwest Elite (1)
2027 BioMidwest Standard (1)
2027 Bio NC Standard (2)
2027 Biotech Bay Elite (1)
2027 Biotech Bay Standard (3)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Genetown Standard (5)
2027 Pharm Country Elite (2)
2027 Pharm Country Premier (1)
2027 Pharm Country Standard (6)
Academia (2982)
Academic (1)
Accelerated approval (55)
Adcomms (37)
Allergies (186)
Alliances (53769)
ALS (232)
Alzheimer's disease (1933)
Antibody-drug conjugate (ADC) (532)
Approvals (18457)
Artificial intelligence (787)
Autoimmune disease (336)
Automation (60)
Bankruptcy (391)
Best Places to Work (12424)
BIOSECURE Act (23)
Biosimilars (240)
Biotechnology (448)
Bladder cancer (208)
Brain cancer (82)
Breast cancer (827)
Cancer (6412)
Cardiovascular disease (541)
Career advice (2420)
Career pathing (50)
CAR-T (370)
CDC (72)
Celiac Disease (3)
Cell therapy (1012)
Cervical cancer (53)
Clinical research (75483)
Collaboration (2295)
Company closure (6)
Compensation (1483)
Complete response letters (100)
COVID-19 (3019)
CRISPR (122)
C-suite (1244)
Cystic fibrosis (165)
Data (8493)
Decentralized trials (3)
Denatured (50)
Depression (188)
Dermatology (95)
Diabetes (643)
Diagnostics (7452)
Digital health (63)
Diversity (12)
Diversity, equity & inclusion (47)
Drug discovery (378)
Drug pricing (243)
Drug shortages (37)
Duchenne muscular dystrophy (314)
Earnings (96018)
Editorial (75)
Employer branding (21)
Employer resources (163)
Events (128939)
Executive appointments (1165)
FDA (22092)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (18)
Frontotemporal dementia (36)
Funding (1886)
Gene editing (263)
Generative AI (69)
Gene therapy (823)
GLP-1 (1210)
Government (5353)
Grass and pollen (7)
Guidances (416)
Healthcare (20721)
HIV (87)
Huntington's disease (63)
Idiopathic pulmonary fibrosis (2)
IgA nephropathy (110)
Immunology and inflammation (339)
Immuno-oncology (110)
Indications (201)
Infectious disease (3406)
Inflammatory bowel disease (237)
Inflation Reduction Act (17)
Influenza (147)
Intellectual property (311)
Interviews (505)
IPO (17484)
IRA (58)
Job creations (4081)
Job search strategy (1985)
JPM (72)
Kidney cancer (21)
Labor market (111)
Layoffs (645)
Leadership (51)
Legal (9219)
Liver cancer (110)
Longevity (34)
Lung cancer (854)
Lymphoma (452)
Machine learning (64)
Management (63)
Manufacturing (1168)
MASH (212)
Medical device (14982)
Medtech (15126)
Mergers & acquisitions (21500)
Metabolic disorders (1702)
mRNA (260)
Multiple sclerosis (202)
NASH (21)
Neurodegenerative disease (485)
Neuropsychiatric disorders (124)
Neuroscience (3627)
Neurotech (1)
NextGen: Class of 2026 (7391)
Non-profit (5023)
Now hiring (79)
Obesity (816)
Opinion (354)
Ovarian cancer (241)
Pain (278)
Pancreatic cancer (336)
Parkinson's disease (404)
Partnered (35)
Patents (636)
Patient recruitment (730)
Peanut (68)
People (63443)
Pharmaceutical (116)
Pharmacy benefit managers (37)
Phase 1 (23560)
Phase 2 (33026)
Phase 3 (24671)
Pipeline (9494)
Policy (376)
Postmarket research (3011)
Preclinical (10215)
Press Release (71)
Prostate cancer (340)
Psychedelics (66)
Radiopharmaceuticals (368)
Rare diseases (1218)
Real estate (6553)
Recruiting (76)
Regulatory (28670)
Reports (64)
Research institute (2714)
Resumes & cover letters (467)
Rett syndrome (40)
RNA editing (29)
RSV (98)
Schizophrenia (193)
Series A (319)
Series B (231)
Service/supplier (24)
Sickle cell disease (125)
Special edition (31)
Spinal muscular atrophy (182)
Sponsored (52)
Startups (4043)
State (2)
Stomach cancer (21)
Supply chain (140)
Tariffs (102)
The Weekly (114)
Vaccines (1276)
Venture capital (125)
Weight loss (549)
Women's health (134)
Worklife (23)
Date
Today (133)
Last 7 days (778)
Last 30 days (3575)
Last 365 days (32243)
2026 (14974)
2025 (32407)
2024 (37580)
2023 (42136)
2022 (53493)
2021 (58262)
2020 (57071)
2019 (50269)
2018 (38191)
2017 (35210)
2016 (35180)
2015 (41106)
2014 (34981)
2013 (30229)
2012 (32390)
2011 (32900)
2010 (31039)
Location
Africa (967)
Alabama (101)
Alaska (7)
Arizona (380)
Arkansas (16)
Asia (45549)
Australia (7750)
California (14099)
Canada (3927)
China (1517)
Colorado (604)
Connecticut (631)
Delaware (433)
Europe (102868)
Florida (2090)
Georgia (458)
Hawaii (4)
Idaho (66)
Illinois (1175)
India (96)
Indiana (640)
Iowa (25)
Japan (575)
Kansas (139)
Kentucky (55)
Louisiana (49)
Maine (76)
Maryland (1716)
Massachusetts (10273)
Michigan (387)
Minnesota (773)
Mississippi (7)
Missouri (161)
Montana (37)
Nebraska (29)
Nevada (152)
New Hampshire (91)
New Jersey (3715)
New Mexico (33)
New York (3700)
North Carolina (1882)
North Dakota (11)
Northern California (7021)
Ohio (425)
Oklahoma (26)
Oregon (51)
Pennsylvania (2798)
Puerto Rico (29)
Rhode Island (54)
South America (1349)
South Carolina (88)
South Dakota (2)
Southern California (5544)
Tennessee (221)
Texas (2275)
United States (50220)
Utah (421)
Vermont (1)
Virginia (354)
Washington D.C. (87)
Washington State (1165)
West Virginia (4)
Wisconsin (155)
Wyoming (2)
800,857 Results for "helsinn therapeutics us inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Helsinn appoints Giacomo Braglia to the Board of Directors
April 16, 2026
·
2 min read
Press Releases
Helsinn announces European Commission approval of AKYNZEO® Oral Suspension
February 18, 2026
·
2 min read
Press Releases
Helsinn and ESTEVE expand their partnership extending the Distribution and Licence Agreement for AKYNZEO® and ALOXI® to Austria
February 9, 2026
·
4 min read
Press Releases
Helsinn announces new Executive Leadership Team as it celebrates 50 years
January 13, 2026
·
3 min read
Press Releases
Helsinn and MagnaPharm enter long-term agreement for AKYNZEO® and ALOXI® across five Central and Eastern European countries
February 11, 2026
·
4 min read
Press Releases
PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neurosciences, Inc. (NASDAQ: JUNS) in a Transaction Valued at Over $100 Million
May 20, 2026
·
7 min read
Helsinn Group announces AKYNZEO® (fosnetupitant/palonosetron) injection is now available in a ready-to-use vial in the US
Helsinn Group (“Helsinn”), a global pharmaceutical company with a track record of over forty-five years of commercial execution and a strong focus in supportive care, oncology and dermato-oncology, is pleased to announce that AKYNZEO® (fosnetupitant/palonosetron) injection is now available in the US in a ready-to-use vial.
June 24, 2024
·
5 min read
Press Releases
Autonomix Medical, Inc. Granted U.S. Patent for Transvascular Monitoring and Treatment Systems with Real-Time Procedural Validation
May 19, 2026
·
5 min read
Press Releases
Outlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
June 1, 2026
·
6 min read
Press Releases
Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in IgA Nephropathy
May 28, 2026
·
13 min read
1 of 80,086
Next
